Boston VC SV Life Sciences raises $274M toward its sixth startup fund

Boston Harbor
Boston Harbor

SV Life Sciences has raised well over half of the $400 million it announced it was seeking last year for its sixth life science upstart fund--but this falls below previous targets that have been around the $500 million mark.

The VC firm, which has offices in Boston and London, has so far raised $274 million, according to federal filings--but is still off its 2015 stated goal of reaching $400 million. Its previous round, which closed back in 2010, raised $523 million.

With that purse, SV took stakes in the ophthalmology-focused KalVista Pharmaceuticals, dermatology biotech Thesan Pharmaceticals and oncology innovator Sutro Biopharma, among others.

Over the past two years, the firm has seen Entellus Medical ($ENTL) execute a $78 million IPO, Convergence Pharmaceuticals go to Biogen ($BIIB) for up to $675 million and OncoEthix get bought by Merck ($MRK) in a $375 million deal.

SV Life Sciences now has about $2 billion under management. There are 24 investors in the latest fund, according its SEC filing.

- check out the SEC Form-D

Related Article:
SV Life Sciences sets out for $400M to fuel biotech bets

Suggested Articles

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

Regeneron's latest cholesterol fighter cut "bad" cholesterol in half for patients with a rare genetic disorder, including in hard-to-treat…

J&J plans to have a vaccine in the clinic by September and win emergency use authorization early next year.